Kamada (NASDAQ:KMDA) Stock Price Passes Below 50 Day Moving Average – Time to Sell?

Kamada Ltd. (NASDAQ:KMDA)’s share price crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $7.66 and traded as low as $7.30. Kamada shares last traded at $7.31, with a volume of 35,012 shares changing hands.

Analyst Upgrades and Downgrades

A number of research firms recently commented on KMDA. Wall Street Zen downgraded Kamada from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd. Benchmark restated a “buy” rating on shares of Kamada in a report on Thursday, March 12th. Stifel Nicolaus set a $11.00 price objective on Kamada in a research note on Wednesday, March 11th. Finally, Weiss Ratings cut Kamada from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 25th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $12.00.

Kamada Stock Performance

The stock has a market cap of $411.20 million, a P/E ratio of 20.43, a P/E/G ratio of 0.67 and a beta of 0.85. The stock’s fifty day moving average is $7.63 and its 200 day moving average is $8.04.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.05). The company had revenue of $45.24 million for the quarter, compared to the consensus estimate of $46.72 million. Kamada had a return on equity of 7.73% and a net margin of 11.21%. Equities research analysts predict that Kamada Ltd. will post 0.44 EPS for the current year.

Institutional Trading of Kamada

A number of institutional investors have recently bought and sold shares of the stock. Y.D. More Investments Ltd boosted its stake in Kamada by 7.3% during the fourth quarter. Y.D. More Investments Ltd now owns 289,382 shares of the biotechnology company’s stock worth $2,050,000 after buying an additional 19,717 shares during the period. Marshall Wace LLP lifted its holdings in shares of Kamada by 25.9% in the 4th quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company’s stock worth $1,390,000 after acquiring an additional 40,514 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Kamada by 43.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 167,521 shares of the biotechnology company’s stock worth $1,183,000 after purchasing an additional 50,608 shares during the period. Huntleigh Advisors Inc. boosted its stake in shares of Kamada by 5.5% during the 4th quarter. Huntleigh Advisors Inc. now owns 149,374 shares of the biotechnology company’s stock worth $1,055,000 after purchasing an additional 7,812 shares during the period. Finally, Two Sigma Investments LP grew its holdings in Kamada by 4.3% during the 3rd quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock valued at $761,000 after purchasing an additional 4,504 shares during the last quarter. 20.38% of the stock is currently owned by institutional investors.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma?derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha?1 antitrypsin augmentation therapy approved by the U.S.